Page last updated: 2024-08-17

cytidine monophosphate and Anemia, Refractory, with Excess of Blasts

cytidine monophosphate has been researched along with Anemia, Refractory, with Excess of Blasts in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Furuyama, K; Harigae, H; Ishizawa, K; Kadowaki, I; Kimura, J; Nomura, J; Okuda, M; Sasaki, O; Sasaki, T; Shishido, T	1
Abe, T; Fukumi, S; Matsuo, A; Mizorogi, F; Sato, H	1
Harada, M; Isokawa, M; Kimura, F; Kojima, K; Ohmoto, E; Takaba, S; Takeuchi, M; Tanimizu, M	1
Kamiya, K; Kawai, Y; Nakamura, T; Sugiyama, M; Tsutani, H; Ueda, T; Urasaki, Y; Wataya, S	1
Azuma, T; Hara, M; Kojima, K; Narumi, H; Shinagawa, K	1

Trials

1 trial(s) available for cytidine monophosphate and Anemia, Refractory, with Excess of Blasts

Article	Year
[A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:4 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Bone Marrow; Cytidine Monophosphate; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Pilot Projects; Risk	1998

Article

Year

[A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:4

Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Bone Marrow; Cytidine Monophosphate; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Pilot Projects; Risk

1998

Other Studies

4 other study(ies) available for cytidine monophosphate and Anemia, Refractory, with Excess of Blasts

Article	Year
[Complete remission by cytarabine ocfosfate plus G-CSF therapy in a patient with hypoplastic RAEB-T]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1 Topics: Administration, Oral; Aged; Anemia, Refractory, with Excess of Blasts; Arabinonucleotides; Cytidine Monophosphate; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Prodrugs; Remission Induction	1995
[Refractory anemia with excess myeloblast in transformation induced remission by combined oral administration of cytarabine ocfosfate and 6-mercaptopurine]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7 Topics: Administration, Oral; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Mercaptopurine; Middle Aged; Remission Induction	1995
[Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1 Topics: Acute Disease; Administration, Oral; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Leukemia; Middle Aged	1995
Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Cancer research, 1994, Jan-01, Volume: 54, Issue:1 Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Polycythemia Vera	1994